Hosted on MSN10mon
Why Dyne Therapeutics, With A 166% Run This Year, Just Catapulted Again
After six months, DYNE-251 recipients reached higher levels of dystrophin than patients in a separate study of Sarepta's Exondys 51. Dyne stock, which has already more than doubled this year ...
BioSpace14d
Dyne’s Duchenne Exon Skipping Oligomer Shows ‘Differentiated’ Clinical Effect
Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...